Table 8  List of in vivo studies in which the therapeutic potential of the administration of hMSCs for the treatment of autoimmune visual and auditory disorders was evaluated.
References   Autoimmune disease   Source of hMSC   Variables   Experimental model   Clinical effects   Mechanism proposed
(163)  Autoimmune uveitis  Bone marrow  None  Mice  ↓Histological disease score  ↑MHC class IIloLy6G−Ly6ChiCD11b+ cells in draining lymph nodes↓CD4+ cell proliferation↑CD4+ cell apoptosis↓CD4+IFN-γ+ Th1 cells↓CD4+IL-17+ Th17 cells
(81)  Autoimmune uveitis  Embryonic stem cells  None  Mice  ↓Fundoscopic score↓Histological disease score  ↓T-cell proliferation↓CD83 up-regulation in dendritic cells↓IL-12↑CD4+CD25+FoxP3+ Treg cells
(150)  Autoimmune uveitis  Bone marrow  None  Mice  ↓Autoimmune uveitis incidence↓Histological disease score↑Cumulative survival rate of corneal grafts  ↑MHC classII+B220+CD11b+IL-10+ monocytes and macrophages with T-cell–suppressive activities
(151)  Autoimmune hearing loss  Adipose tissue  None  Mice  ↓Auditory brainstem responses threshold↓Cochlear pathology  ↓Proliferation of antigen-specific Th1 cells↓Proliferation of antigen-specific Th17 cells↑IL-10 production in splenocytes↑Generation of antigen-specific CD4+CD25+Foxp3+ Treg cells
Both the methodology employed and the results obtained by each article are represented in this table.